CONTENTS

ABSTRACT vi

LIST OF FIGURES viii

LIST OF TABLES ix

ACKNOWLEDGEMENT x

CHAPTER 1: INTRODUCTION 1

CHAPTER 2: LITERATURE REVIEW 7

2.1 Epidemiology

A) Global scenario 7

B) Malaysian scenario 8

2.2 Etiological factors 10

2.2.1 Risk habits

A) Tobacco 10

B) Alcohol 11

C) Quid Chewing 12

D) The Trio – tobacco, alcohol and quid 14

2.2.2 Infections 14

A) Viruses 14

B) Bacteria 16

C) Fungal 17
2.2.3 Genetic Predispositions
2.2.4 Mouthrinse
2.2.5 Dental Factors
2.2.6 Diet and nutrition
2.2.7 Immunosuppression
2.2.8 Others

2.3 Oral squamous cell carcinoma – diagnosis, prognosis and survival

2.4 Oral carcinogenesis – cellular and molecular basis
2.4.1 Cellular basis of oral carcinogenesis
2.4.2 Molecular event of oral carcinogenesis
2.4.2.1 Cell cycle control
2.4.2.2 Measuring proliferative rate
   A) Ki-67
   B) Ki-67 – proliferative cum prognostic marker
2.4.2.3 Tumour suppressor genes (TSGs)
   A) Molecule of the year 1993, the p53.
   B) p53, the discovery
   C) p53 protein
   D) p53 network
   E) p53 – a prognostic marker?
2.4.2.4 Murine Minute Double 2, the MDM-2 gene
   A) Expression of MDM- protein in cancers
2.4.2.5 Apoptosis
2.4.2.6 Bcl-2 protein family
   A) Bcl-2
CHAPTER 3: MATERIALS AND METHODS

3.1 Samples selection
   A) Inclusion criteria
   B) Exclusion criteria

3.2 Data collection

3.3 Laboratory procedures
   3.3.1 Specimens processing
   3.3.2 Staining procedures
      a) Haematoxylin and Eosin (H&E) staining
      b) Immunohistochemistry staining
         i) Ki-67
         ii) p53
         iii) Bcl-2
         iv) MDM-2
   3.5 Histopathological and Immunohistochemistry Evaluation
      A) Broders’ Classification
      B) Pattern of invasion
      C) Immunohistochemical evaluation

3.6 Statistical analysis

CHAPTER 4: RESULTS
4.1 Demographic characteristics

4.2 Clinicopathological features
   A) TNM Staging with T and N status
   B) Broders Classification
   C) Pattern of Invasion

4.3 Immunohistochemical expression
   A) Ki-67 Labeling Index (LI)
   B) p53 expression
   C) MDM-2 expression
   D) Bcl-2 expression

4.4 Relationship between Ki-67 status or Labeling Index (LI) and overexpression of p53, MDM-2 and Bcl-2.

4.5 Relationship between Ki-67 status or Labeling Index (LI) and overexpression of p53/Bcl-2, p53/MDM-2 and MDM-2/Bcl-2

4.6 Relationship of demographic and clinicopathological parameters with Ki-67 status, overexpression of p53, MDM-2 and Bcl-2

4.7 Relationship of demographic and clinicopathological parameters with combined expression of the markers.

CHAPTER 5: DISCUSSION

5.1 Sample size

5.2 Age

5.3 Gender and Ethnicity

5.4 Sites
5.5 TNM Staging 86

5.6 Broders’ classification & pattern of invasion 86

5.7 Evaluation of expression of Ki-67, p53, MDM-2 and Bcl-2 at the tumour invasive front and relationship to other clinicopathological parameters 87
   A) Ki-67 Labelling Index 87
   B) Expression of p53 89
   C) Expression of MDM-2 92
   D) Expression of Bcl-2 94

5.8 Evaluation of coexpression Ki-67, MDM-2, p53 and Bcl-2 at the tumour invasive front in relation to clinicopathological parameters. 96
   A) MDM-2 and p53 expression 96
   B) p53 expression, Ki-67 LI and Bcl-2 expression 97

CHAPTER 6: CONCLUSION & RECOMMENDATIONS 100

CHAPTER 7: REFERENCES 102

APPENDIX 130